Ulcavis, 120 mg 28 pcs

• Gastric and duodenal ulcers in the acute phase, including those associated with Helicobacter pylori.
• Cronic gastritis and gastroduodenitis in the acute phase, including associated with Helicobacter pylori.
• Irritable bowel syndrome with predominantly diarrheal symptoms.
• Functional dyspepsia not associated with organic gastrointestinal diseases.

.

Active ingredient

Bismuth tricalium dicitrate

Composition

per 1 tablet:

Active ingredient:

Bismuth trilium dicitrate 303.03 mg equivalent to bismuth oxide 120.00 mg: justify;”>Bismuth tricalium dicitrate 303.03 mg, equivalent to bismuth oxide 120.00 mg

Associates:

Corn starch, povidone K-30, potassium polycryline, macrogol-6000, magnesium stearate

Shell film:

Opadray II clear*, titanium dioxide (E171)

Opadray II transparent:”

Polyvinyl alcohol, macrogol-4000, talc

How to take, the dosage

Adults and children over 12 years take Ulcavis^® 1 tablet 4 times daily 30 minutes before meals and at night or 2 tablets 2 times daily 30 minutes before meals.

Children from 8 to 12 years should take Ulcavis^® 1 tablet 2 times daily 30 minutes before meals.

Children from 4 to 8 years are prescribed in a dose of 8 mg/kg/day, depending on the body weight of the child, 1-2 tablets per day (respectively, in 1-2 doses per day). In this case, the daily dose should be as close as possible to the calculated dose (8 mg/kg/day).

The tablets are taken 30 minutes before the meal with some water.

The course of treatment is 4-8 weeks. During the next 8 weeks you should not use any medicines containing bismuth.

For eradication of Helicobacter pylori, it is reasonable to use the drug Ulcavis^® in combination with other antibacterial agents with anti-Helicobacter activity (as recommended by the doctor).

Interaction

Within half an hour before and after taking the drug Ulcavis^® it is not recommended to use other medicines or take food and liquid, particularly antacids, milk, fruit and fruit juices. This is because if they are taken orally at the same time, they may affect the effectiveness of the drug Ulcavis^®.

Simultaneous use of Ulcavis^® with tetracycline reduces absorption of the latter.

Special Instructions

Contraindicated in children under 4 years of age.

Children over 12 years should take Ulcavis^® 1 tablet 4 times daily 30 minutes before meals and at night or 2 tablets 2 times daily 30 minutes before meals.

Children from 8 to 12 years should take Ulcavis^® 1 tablet 2 times daily 30 minutes before meals.

Children from 4 to 8 years are prescribed in a dose of 8 mg/kg/day, depending on the body weight of the child, 1-2 tablets per day (respectively, in 1-2 doses per day). The daily dose should be as close as possible to the calculated dose (8 mg/kg/day)

It is contraindicated in patients with severe renal insufficiency (creatinine clearance less than 30 ml/min),

The drug Ulcavis^® should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment. During treatment with Ulcavis^® you should not use other medicinal products containing bismuth. At the end of a course of treatment with the drug Ulcavis^® in the recommended doses, the concentration of the active substance in the blood plasma does not exceed 3-58 µg/L, and intoxication is observed only when the blood plasma concentration is higher than 100 µg/L.

When using Ulcavis ^®, stool may turn dark due to bismuth sulfide formation. Sometimes a slight darkening of the tongue is noted.

There are no data on the effect of the drug Ulcavis^® on the ability to drive vehicles and machines.

Synopsis

Round slightly biconvex film-coated tablets, white or almost white, odorless or faintly ammonia odor, with bevel.

Break appearance: a rough mass of white color.

Contraindications

Severe renal failure (creatinine clearance less than 30 ml/min), pregnancy, breastfeeding, individual intolerance to the drug, children under 4 years of age.

Side effects

From the digestive system: nausea, vomiting, more frequent stools, constipation are possible. These phenomena are not dangerous to health and are temporary.

Allergic reactions:skin rash, skin itching.

Long-term use in high doses may lead to encephalopathy associated with the accumulation of bismuth in the central nervous system.

Overdose

When the drug is used in doses ten times higher than recommended, or when overdosed, bismuth poisoning may develop.

Symptoms: dyspepsia, skin rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums. Overdose of Ulcavis^®, caused by long-term use of doses exceeding the recommended ones, may lead to renal dysfunction. These symptoms are completely reversible when Ulcavis^® is discontinued.

Treatment: In case of signs of poisoning it is necessary to flush the stomach, take activated charcoal and saline laxatives. Further treatment should be symptomatic. In case of renal dysfunction accompanied by high concentration of bismuth in blood plasma, chelators (penicillamine, sodium dimercaptopropane sulfonate) may be prescribed. Hemodialysis is indicated in case of severe renal dysfunction.

Pregnancy use

The use of Ulcavis^® in pregnancy and during breastfeeding is contraindicated.

Similarities

De-Nol, Novobismol, Ulcavis, Escape, Vitridinol, Bismuth tricalium dicitrate